Generic filters
Filter by content type
Taxonomy terms

TALS – Talaris Therapeutics Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 14.5

Low: 7

High: 23

Total Analysts: 3

Company Profile

Talaris Therapeutics, Inc. is a late-clinical stage, cell therapy company. The Company is engaged in developing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Its therapeutic approach, allo-HSCT therapy prevents organ rejection without the morbidity and mortality that has been associated with the use of anti-rejection medicines, also known as chronic immunosuppression. Allo-HSCT is used to replace diseased immune, blood or stem cells in patients with severe immune, blood or metabolic disorders. The Company’s lead product candidate, FCR001, which is central to its Facilitated Allo-HSCT Therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation. It is advancing a pipeline of programs across three therapeutic categories: solid organ transplantation, severe autoimmune disease, and severe non-malignant blood, immune and metabolic disorders.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan